Lunning: [In] the ZUMA-7 trial, the key eligibility for the patients was [being] relapsed or refractory to primary therapy within 1 year of completion. They had to declare that they intended to proceed to an autologous stem cell transplant [ASCT]. There was stratification [by response...
Caron A. Jacobson, MD, instructor in medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, and first author of the study presented at ASH, said that in a real-world setting, eligibility criteria and patient management factors may be very distinct from a clinical trial setting....
Clinical trial eligibility and exclusion criteria Inclusion criteria (1) Disease status (i) Dose-escalation phase and DIPG expansion cohort: tissue diagnosis of H3K27M-mutated DIPG with radiographically evident tumour restricted to the brainstem, or (ii) Dose-escalation phase and spinal DMG exp...
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potentially prevent this, but the clinical safety...
so almost 400 patients with real-world experience. And a large number of those were not eligible for the clinical trial eligibility criteria, which I think is the key factor because that’s the art of medicine translating from an FDA approval, which just says twice-relapsed large cell lymphoma...
Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in B
The FDA has approved an individual patient IND, allowing for a second dose of a novel FSHR-targeting CAR T-cell therapy for the treatment of a patient with recurrent ovarian cancer that may be demonstrating clinical activity to the initial treatment.1 The CAR T-cell therapy is currently und...
This review aims to examine the persistent disparities noted in clinical trial enrollment, with particular focus on lymphoid malignancies, CAR-T cell and bispecific antibody therapies.Targeted interventions can enhance recruitment of underrepresented groups in clinical trials and address the complex barriers...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key am